Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.

Overview

Aprepitant was initially developed to prevent chemotherapy-induced nausea and vomiting (CINV). However, its applications have since broadened to include postoperative nausea and vomiting (PONV). Aprepitant belongs to the neurokinin-1 antagonist class of medications and has received approval from the Food and Drug Administration (FDA) for both indications. This activity outlines and reviews the indications, actions, and contraindications of aprepitant as a valuable drug in preventing CINV and PONV. This activity also highlights the mechanism of action, adverse event profile, monitoring, and relevant interactions pertinent for healthcare team members involved in the care of patients undergoing highly emetogenic chemotherapy or general anesthesia.